RCEL (AVITA Medical) Short Interest


RCEL AVITA Medical Inc RCEL
66 GF Score
Price $3.95
GF Value $10.78
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is AVITA Medical Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

RCEL vs NNOX, MXCT, SNWV: Short Interest Comparison

For the Medical Devices subindustry, AVITA Medical's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AVITA Medical Short Interest vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AVITA Medical's Short Interest distribution charts can be found below:

* The bar in red indicates where AVITA Medical's Short Interest falls into.


RCEL
66GF Score
AVITA Medical Inc RCEL
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AVITA Medical (RCEL) Overvalued in 2026?

Based on GuruFocus' analysis, AVITA Medical stock appears to be undervalued. The current stock price of $3.95 is trading 63.4% below its estimated GF Value™ of $10.78. GuruFocus considers AVITA Medical to be Possible Value Trap.

Key valuation signals for RCEL:

  • Short Interest:
  • GF Value™: $10.78 vs. price of $3.95 (63.4% below fair value)
  • GF Score™: 66/100 with 6 warning signs

No single metric tells the full story. See the RCEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AVITA Medical Business Description

Address 28159 Avenue Stanford, Suite 220, Valencia, Santa Clarita, CA, USA, 91355
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
66GF Score

Get the complete analysis for RCEL

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.95
Price
$10.78
GF Value